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Background On-site source data verification is a common and expensive activity,
with little evidence that it is worthwhile. Central statistical monitoring (CSM) is a
cheaper alternative, where data checks are performed by the coordinating centre,
avoiding the need to visit all sites. Several publications have suggested methods for
CSM; however, few have described their use in real trials.
Methods R-programs were created to check data at either the subject level (7 tests
within 3 programs) or site level (9 tests within 8 programs) using previously described
methods or new ones we developed. These aimed to find possible data errors such as
outliers, incorrect dates, or anomalous data patterns; digit preference, values too close
or too far from the means, unusual correlation structures, extreme variances which
may indicate fraud or procedural errors and under-reporting of adverse events. The
methods were applied to three trials, one of which had closed and has been published,
one in follow-up, and a third to which fabricated data were added. We examined how
well the methods work, discussing their strengths and limitations.
Results The R-programs produced simple tables or easy-to-read figures. Few data
errors were found in the first two trials, and those added to the third were easily
detected. The programs were able to identify patients with outliers based on single or
multiple variables. They also detected (1) fabricated patients, generated to have values
too close to the multivariate mean, or with too low variances in repeated measure-
ments, and (2) sites which had unusual correlation structures or too few adverse
events. Some methods were unreliable if applied to centres with few patients or if data
were fabricated in a way which did not fit the assumptions used to create the pro-
grams. Outputs from the R-programs are interpreted using examples.
Limitations Detecting data errors is relatively straightforward; however, there are
several limitations in the detection of fraud: some programs cannot be applied to
small trials or to centres with few patients (\10) and data falsified in a manner
which does not fit the program’s assumptions may not be detected. In addition,
many tests require a visual assessment of the output (showing flagged participants
or sites), before data queries are made or on-site visits performed.
Conclusions CSM is a worthwhile alternative to on-site data checking and may be
used to limit the number of site visits by targeting only sites which are picked up by
the programs. We summarise the methods, show how they are implemented and
that they can be easy to interpret. The methods can identify incorrect or unusual
data for a trial subject, or centres where the data considered together are too differ-
ent to other centres and therefore should be reviewed, possibly through an on-site
visit. Clinical Trials 2013; 10: 783–806. http://ctj.sagepub.com
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Substantial resources are spent conducting clinical
trials, due in part to current guidelines and regula-
tions. International Conference on Harmonisation–
Good Clinical Practice (ICH-GCP) [1] requires that
the data be ‘accurate, complete, and verifiable from
source documents’. A statement adhered to by many
organisations is, ‘In general there is a need for on-
site monitoring, before, during, and after the trial’.
Although site visits can be useful to examine proce-
dures for safety reporting and drug labelling, for ver-
ifying pharmacy supplies, and performing other
monitoring tasks, considerable effort is typically spent
checking trial data with patient records, i.e., source
data verification. Although some organisations use
source data verification for a random sample of parti-
cipants (e.g. 20%), others still perform 100% checks.
A clinical trial database can never be completely free
from errors. Monitoring of trial data is used to mini-
mise errors, but also can be used to check on the pro-
gress of a trial and to detect fraud [2].
Fraud is relatively uncommon. In a survey of sev-
eral thousand US scientists [3], almost 30% admitted
to participating in some questionable research activ-
ity in their career, but only 0.5% admitted to ‘falsify-
ing or ‘‘cooking’’ research data’. Anecdotal evidence
of fraud tends to be limited to small projects where
the researcher has complete control of the data.
Steen [4,5] examined articles between 2000 and
2010 and found that 1 in every 6070 clinical trials
was retracted. From 180 assessable retracted articles
involving humans, there were 9 clinical trials with
.200 participants. Seven [6–12] of these were
retracted for fraud; however, the term ‘fraud’ encom-
passed a wide range of activities, and only two trials
were suspected of falsifying data based on the six
retraction statements available [10,11].
On-site monitoring is a core function of many clin-
ical trial organisations, particularly Contract Research
Organisations and pharmaceutical companies. How-
ever, major data errors are often infrequent, and there
is no reliable evidence that on-site visits influence the
results and study conclusions. Furthermore, random
errors should be balanced between groups in a rando-
mised trial, thus having a negligible effect.
Central Statistical Monitoring (CSM) has been
proposed as a cheaper and more efficient alternative
to on-site data monitoring of all trial sites (centres)
[13]. With CSM, data checks are performed by the
coordinating centre in order to minimise the need
to visit every site. Although ICH-GCP explicitly
allows CSM, the text of that document is not suffi-
ciently permissive: ‘however in exceptional circum-
stances the sponsor may determine that central
monitoring . can assure appropriate conduct of
the trial’. There is a view that, if full on-site
monitoring is not done, the chance of a marketing
license being approved is decreased, and so the costs
of monitoring are considered justified. However,
recent draft guidelines from the Food and Drug
Administration encourage the use of CSM [14].
Several authors have described methods for detect-
ing fraud and data errors [15–18], but few publica-
tions have described CSM in real clinical trials
already completed or in progress and those that do
tend to focus on a particular method to check data
for anomalies, or have not applied the method(s) to
actual trial data.
Al-Marzouki et al. [19] investigated fraud in a trial
evaluating a dietary intervention for patients with
coronary heart disease. They examined the variances
and digit preference and suggested that the data had
been fabricated. However, they focused on the
whole data set, and not by site, which would be one
of the main purposes of CSM in clinical trials. Bailey
[20] investigated suspected fraud in one laboratory
in a multi-centre animal study, using scatter plots to
examine correlations between variables. He showed
that after a suspicious centre had been investigated,
the variance of certain variables increased to a simi-
lar level seen in other laboratories.
Herein, we apply CSM methods, provide a suite of
R-programs, and show how the output from the pro-
grams can be interpreted. We have examined the
simplicity and reliability of the methods, including
their strengths and limitations.
Methods
We classified data monitoring to be at either (1) trial
participant level or (2) site level. A set of R-programs
[21] was developed to implement CSM methods;
the R-programs are freely available from http://
www.ctc.ucl.ac.uk. (‘‘Training’’ section) R is free and
relatively simple to use; the R-programs can be run
without spending significant time tailoring the pro-
grams for an individual study. We intended to
implement a range of data checks without the need
for intensive programming by information technol-
ogy (IT) staff. Tables 1 and 2 list the monitoring
checks we examined, their purpose, and the corre-
sponding R-programs. Appendix A – Text 1 describes
the methods in more detail.
Our first goal was to detect data errors at the parti-
cipant level. Buyse et al. [16] and Baigent et al. [17]
suggested calendar checks to find errors such as dates
that occur on weekends and holidays (when unex-
pected) or in an incorrect order, for example, treat-
ment after death. The R-programs to detect outliers,
that is, observations that appear too large or too
small, were based on univariate (including Grubbs’s
method) and multivariate approaches (using Eucli-
dean and Mahalanobis distances) [15–17].
784 AA Kirkwood et al.
Clinical Trials 2013; 10: 783–806 http://ctj.sagepub.com
 at University College London on June 25, 2015 ctj.sagepub.com Downloaded from Site (centre)-level data monitoring checks aim to
(1) identify systematic errors in trial conduct (proce-
dural errors) at a site, which could be due to a genu-
ine misunderstanding of the trial protocol by local
staff, and (2) detect fraud resulting from fabricating
trial participants and/or data or creating data for
missing values of actual participants [16]. We
applied these methods to individual trial sites, but
they also could be applied to individual investigators
or geographical regions. These checks are intended
to flag sites discrepant to the other sites by looking
for unusual data patterns, possibly triggering an on-
site visit to check the procedures and original data.
The methods include examining correlation struc-
tures [16–18] using a method described by Taylor
et al. [18], digit preference [15–17] (including Ben-
ford’s law [22]), and inliers [15], that is, participants
with several variables whose values lie close to the
mean. We also implemented methods to detect pro-
cedural errors to identify sites that rounded too
many continuous measurements [18] and for
repeated continuous measurements, that is, data for
a participant with too little variability over time
[15,16,20].
Reporting and monitoring adverse events is an
important activity in clinical trials. Over-reporting
may indicate that site staff are being overly cautious
about classifying adverse events, which creates extra
work to process reports. However, under-reporting is
potentially serious and could affect the trial conclu-
sions as well as regulatory responsibilities. We exam-
ined the number of serious adverse events (SAEs) per
site based on the number of participants recruited,
and the length of time in the trial. We calculated
and SAE rate for each site as the number of partici-
pants with at least one SAE divided by the total
number recruited, and divided further by trial dura-
tion at that site. Another method developed used
the time each participant spent in the trial.
The methods described above were applied to
three phase III cancer trials, in which overall survi-
val was the main end point:
Table 1. Summary of the methods described for participant-level data monitoring and the situations they can be applied to
Recording and entry errors Procedural errors Fraud R-program
Participant-level data monitoring
Dates – order checking
a UU U date_order_check
Dates weekend_hol_check
Weekends
a UU (option: weekends)
National holidays
a UU (option: holiday)
Outliers outlier_check
Using standard deviation UU (option: sd)
Grubbs’ method UU (option: grubbs)
Multivariate – Euclidean distance UU (option: euclid)
Multivariate – Mahalanobis distance UU (option: mahal)
aMethods developed by the authors.
Table 2. Summary of the methods described for centre-level data monitoring and the situations they can be applied to
Recording and entry errors Procedural errors Fraud R-program
Centre-level data monitoring
Digit preference – integers (rounding) UU integer_check
Digit preference: (1) Benford’s law and
(2) comparison with all other sites
a
U digit_preference
Comparison of variable means mean_check
Chernoff faces UU (option: faces)
star plots UU (option: star)
Inliers U inlier_check
Adverse event rates
a U SAE_check
Correlation checks U correlation_check
Variance checks UU variance_check
Categorical variables
a UU U cat_check
SAE: serious adverse event.
aMethods developed by the authors.
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with small-cell lung cancer, randomised to
receive thalidomide or placebo, in addition to
standard chemotherapy. Patients were recruited
from 79 centres (2003–2006).
  ABC-02 [24]: an unblinded trial of 324 patients
with advanced biliary tract cancer, comparing
gemcitabine/cisplatin with gemcitabine. Here, we
also manually created data errors and fabricated
patients (one person created them, and another
who was blind to the errors ran the R-programs to
identify them). Patients were recruited from 37
centres (2002–2008).
  TOPICAL [25]: a double-blind trial of 670
patients with non-small cell lung cancer that
was ongoing at the time of our assessment of
CSM. It compared Tarceva with placebo, among
patients considered unfit for chemotherapy. The
monitoring findings were checked in real-time
with data queries sent to centres. Patients were
recruited from 78 centres (2005–2009).
Because Study 12 and ABC-02 had closed already,
data could be examined only retrospectively; thus,
queries about anomalous or suspicious data were not
sent to sites that participated in those trials. We
describe how output from the R-programs which
apply CSM methods were interpreted. We also pro-
vide a summary of their main strengths and limita-
tions in Table 3. We refer to ‘real’ data as those
observed from the trials, as opposed to fabricated data
that were manually created to evaluate the programs.
Results
Participant-level data monitoring
Dates: ordering, weekends, and national holidays
We examined whether dates of randomisation, blood
test results, chemotherapy, and follow-up appoint-
ments occurred on weekends or holidays and whether
there were obvious date ordering errors. The
R-program produces tables listing the discrepancies.
Very few errors were detected (Table 4) particularly in
the Study 12 database, which already had been
cleaned and analysed. Weekend and holiday dates
f r o mt h eT O P I C A Lt r i a lw e r eq u e r i e d ,s o m ew e r e
found to be correct (often inpatient treatment), and
some were data errors. For Study 12, after inspecting
paper case report forms (CRFs) several dates would
have been changed. However, there were only 13 liv-
ing patients for whom any of these dates would be
used in survival analyses and corrections would likely
have a negligible effect on the results.
Outliers
Several univariate continuous variables were exam-
ined; Figures 1(a) and (b) provide examples of the
output (outliers are shown as solid points). The
number of data points considered to be outliers
using the 6k Standard Deviation (SD) method was
478 (0.93% of all data values) and 148 (1.6%) in
Study 12 and TOPICAL respectively. Using Grubbs’s
test, these numbers increased to 2056 (4%) in Study
12 and 425 (3.3%) in TOPICAL. However, none of
these variables were used in the primary analyses.
Twenty fabricated values were added to the vari-
able ‘haemoglobin’ in the ABC-02 trial by an inde-
pendent statistician who made them ‘extreme’.
The R-program detected 13 out of 20 using a 63
SD cut-off; the other 7 were found after the 13 had
been replaced with their genuine values. All 20
were detected immediately when the cut-off was
62 SDs (Figure 1(b)) or when Grubbs’s test was
used at 63 SDs because the larger false values were
removed after each iteration of the program and
no longer masked the less extreme outliers. No
genuine data values were picked up as outliers with
either method. Both methods require the data to
be Normally distributed, so our R-programs pro-
duce Normal probability plots and histograms.
When the data clearly are not distributed Nor-
mally, the program could be re-run to detect out-
liers that lie more than k 3 inter-quartile range,
that is, above and below the upper and lower
quartiles.
The R-programs also can be used to check several
continuous variables for participants simultaneously
(multivariate outliers). We used data from several
CRFs for each of the three trials (example in
Figure 2). D values, where D is the sum of either the
Normalised Euclidean distances or the Mahalanobis
distance from the mean (Appendix A), which
exceed 62 SDs from the mean D are automatically
shown in red. A list of participants with large D
values is also produced. For example, only 13 of 658
patients (2%) using the Euclidean distance and 8
(1.2%) using the Mahalanobis distance were flagged
as multivariate outliers in the TOPICAL trial using
19 pretreatment variables simultaneously. A partici-
pant identified in both the univariate and multivari-
ate outlier programs could be flagged for particular
attention.
Site-level data monitoring
Rounding and digit preference
The R-program to identify rounding [18] was
applied to all of the continuous variables on two
CRFs in Study 12. In the example shown in Figure 3,
two sites showed a monotonic increase, indicating
no evidence of systematic rounding, but site 68
reported only integer values after the first
observation.
786 AA Kirkwood et al.
Clinical Trials 2013; 10: 783–806 http://ctj.sagepub.com
 at University College London on June 25, 2015 ctj.sagepub.com Downloaded from Table 3. Strengths and limitations of the methods
Strengths Limitations
Participant-level data monitoring
Dates
Order checking
Weekends
National holidays
  A simple spreadsheet is produced
containing all the information needed
to query the results
  Can check a large number of variables
quickly
  May pick up unimportant errors which take time to query
  Within the weekend and national holiday programs, care
needs to be taken to only include dates that you would not
expect to fall on weekends and national holidays
  Will currently only detect UK national holidays; the code
could be adapted for use in other countries
Outliers
Standard Deviation (SD)
method
Grubbs’ test
Inter-quartile range (IQR)
method
Multivariate – using
Euclidean distance
Multivariate – using
Mahalanobis distance
  An easy-to-read spreadsheet is
produced containing all the
information needed to query the
outliers
  Can be arranged by site so that sites
consistently reporting outlying values
can be flagged
  The SD cut-off can be chosen by the
user and changed for different data
sets, perhaps lowered for variables to
be used in the primary analyses
  Several options (univariate: SD,
Grubbs, IQR; multivariate: Euclidean
and Mahalanobis distances) are
available depending on whether the
data are Normally distributed
  May not find all errors if smaller outliers are masked by
bigger ones (SD method), especially in small data sets
  May not be applicable with non-Normally distributed data
(SD, Grubbs)
  The SD cut-off needs to be carefully chosen to avoid
flagging too many real data points
  The multivariate methods may not pick up errors detected
using the univariate methods
Centre-level data monitoring
Digit preference: integers
(rounding)
  Significant rounding can be easily
detected by eye
  Somewhat subjective; however, alterations to the code may
be possible so that only sites with a certain percentage of
rounded values or several consecutive rounded values
would be shown in the output.
  Many plots to examine if a trial has many sites
Digit preference
Benford’s law   Benford’s law is only applicable for variables where the
leading digit can be 1–9, so many clinical trial
variables would not be consistent with this (e.g., blood
pressure). Also, the variable should not be Normally
distributed
Comparison with all
other sites (Either first or
last digit)
  Can also be used to detect rounding,
for example, do sites have lots of
continuous measurements ending with
5o r0 ?
  No underlying assumptions about the
variables (unlike Benford’s law)
  May detect small (unimportant) differences in large sites.
Care needs to be taken to use several methods or examine
several CRFs (comparing which numbers appear preferred)
to ensure there really are problems with a site
  Assumes that investigators falsifying data may show digit
preference
Comparison of variable means
Chernoff faces
Star plots
  Graphical display of several variables
simultaneously
  Difficult to interpret
  Small differences in some features stand out more than
large differences in others (face plots)
  Difficult to read when many variables are used (star plots)
  Both are difficult to read with many sites (may work better
in trials with a small number of sites, 5–10 perhaps)
(continued)
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Strengths Limitations
Inliers   Can detect participants with several
values lying too close to the mean
  Produces Easy-to-read spreadsheets
and plots which give the values of each
variable for inlying participants along
with the mean of the variable
  The program may not automatically flag participants if
several are created lying close to the means; however, they
should show up on the plots.
  The cut-off needs to be carefully chosen so that not too
many participants are flagged
  Will not flag falsified participants if their data values do not
lie close to the means
  Should not be used in sites with small numbers of
participants
  Assumes falsified data would lie close to the means (i.e.,
made to look as similar to the real data as possible)
Adverse event rates   Can detect sites with small numbers of
SAEs in comparison to the number of
participants and the time in the trial
  Produces easy-to-interpret plots and
spreadsheets
  Need to carefully examine the plots and tables (from the
output) to consider whether flagged sites need
investigating
Correlation checks   Adjustable significance limits
  May detect falsified data which appear
acceptable in univariate analysis
  Can only be used for sites with sufficient numbers of
participants (at least 10) so that the correlation matrix is
sufficiently reliable
  Grey-scale plots are subjective to interpret
  Variables with zero or very small SDs are not
appropriate
  Problems if there are small (very close to zero) variances
within some variables, within a site; these variables or sites
will need to be
removed
  The more sites examined, the more likely that a statistically
significant p-value would be found by chance, hence we
suggest using a low p-value cut-off of 0.01
Variance checks   Second option (to look for no change
between observations) also available
  Large outliers may cause problems
  Some subjectivity when interpreting the output
  Needs a reasonably large number of observations per
participant
Categorical variables   Output is easy to interpret   Can only be used in sites with reasonably large numbers of
participants in each level (expected values of at least 5 in
each cell to run a chi-square test)
SAE: serious adverse event; CRF: case report form.
Table 4. Numbers of potential date errors found in the TOPICAL and Study 12 trials
Trial/test Number of
data sheets
Number of
variables
Number of
data values
Number of
errors found (%)
Study 12
Date order 11 29 25,903 61 (0.23)
Weekends 5 21 45,325 308 (0.67)
National holidays 5 21 45,325 50 (0.11)
TOPICAL
Date order 21 47 30,964 191 (0.62)
Weekends 7 15 13,336 288 (2.2)
National holidays 7 15 13,336 49 (0.37)
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ables from several CRFs within Study 12 to identify
digit preferences. When comparing the observed dis-
tribution of leading digits with that expected from
Benford’s law, we flagged sites that had p-values
 0.01 (chi-square test). Table A1 (Appendix A) is the
output for Study 12, where 16 out of 65 sites were
flagged. However, Benford’s law should be used only
for variables where the leading digit can range
between 1 and 9, may take values across a range of
several orders of magnitude, and are not Normally
distributed; assumptions that are unlikely to hold
for many clinical trial variables. In Study 12, for
example, the data overall did not fit Benford’s distri-
bution (p\0.001).
We proposed an alternative method, which com-
pares the observed distribution of leading digits
within each site with that from all other sites. This
does not have the same limitations as Benford’s law,
so all continuous variables could be included
(Appendix A – Table A1). For example, the data from
site 11 (Table 5) would be flagged using Benford’s
law, but when compared with all other sites, its dis-
tribution does not appear to be discrepant; indicated
by the very different p-values, p \ 0.001 versus
p = 0.77. The number of sites that were flagged with
this method was only 3 of 66 (data from the Study
12 chemotherapy CRF) and 1 of 34 (data from the
TOPICAL pretreatment CRF). One site in Study 12
was flagged based on data from the randomisation
and chemotherapy CRFs but, on closer inspection,
did not appear suspicious because the differences
were small and the digit patterns were not similar
between the two CRFs. When a large number of
data values were examined, even a small difference
between the observed and expected proportions
sometimes produced a small p-value, so we con-
cluded that the size of the differences should be
examined as well as the p-values. Our R-program
can also use the last digit of continuous variables
instead of the first digit when examining rounding.
No sites were flagged using this test on data from
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Figure 1. (a) A scatter plot for the Study 12 trial and one continuous variable ‘haemoglobin’ (HB) at baseline. There is only one outlier,
automatically shown as a solid point (coloured red in the R output). (b) A scatter plot for the ABC-02 trial and one continuous variable,
haemoglobin, at baseline. The points automatically shown as a solid point (coloured red in the R output) are outliers (lying .6 2 SD from
the mean). These were all 20 fabricated values that were added to the data set.
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Figure 2. A scatter plot for the TOPICAL trial, based on 19 con-
tinuous variables (on the case report form completed at the start
of treatment). There are 8 potential multivariate outliers (where
D exceeds 62 SDs), shown in red.
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CAL pretreatment CRF.
Comparing means of variables among sites
We implemented three methods for simultaneously
comparing the means of continuous measurements
among centres: Chernoff face plots [26,27], star plots
[27], and parallel coordinate plots (see Appendix A).
However, the results from application of these meth-
ods were difficult to interpret, and two methods
were particularly influenced by outliers. In addition,
numerically small differences in the means of vari-
ables between one site and another could appear
large when displayed as Chernoff faces.
Inliers (data values too close to the means, possibly
indicating fraud)
Figure 4 shows a plot used to identify inliers for the
TOPICAL trial (based on 19 pretreatment blood
values). Similar to the multivariate outlier program,
D, the sum of the Euclidean distances from the
mean, is calculated for each participant, but here we
focus on participants with unusually small D values,
which are more apparent on a log scale. Only one
patient (from site 20, circled in Figure 4) had a
log(Di) value that exceeded 2.5 SDs below the over-
all mean log(D)). The number of inliers for the other
two trials was also low. Closer inspection of data
from patients which were flagged as inliers showed
they came from CRFs with small numbers of contin-
uous variables with just one or two of the values
lying close or equal to the mean.
Because few inliers were found in Study 12 and
TOPICAL, we fabricated patients in ABC-02 which
had data close to the mean values (Appendix A –
Text 1, ‘Inliers’). In a site with few patients (n = 9), a
cut-off of 2 SDs identified all 6 fabricated patients,
and 2.5 SDs flagged four of them. In the site with a
medium number of patients (n = 18), no fabricated
patients were found using a cut-off of 2.5 SDs, but
three were found using 2 SDs. Five fabricated
0 1 02 03 04 05 06 0
0
1
0
3
0
5
0 Site: 60
Patients(in chronological order)
c
u
m
u
l
a
t
i
v
e
 
f
r
e
q
u
e
n
c
y
o
f
 
n
o
n
-
i
n
t
e
g
e
r
s
51 0 1 5 2 0 2 5
5
1
0
1
5
2
0
Site: 63
Patients(in chronological order)
c
u
m
u
l
a
t
i
v
e
 
f
r
e
q
u
e
n
c
y
o
f
 
n
o
n
-
i
n
t
e
g
e
r
s
12345
0
.
6
0
.
8
1
.
0
1
.
2
1
.
4 Site: 68
Patients(in chronological order)
c
u
m
u
l
a
t
i
v
e
 
f
r
e
q
u
e
n
c
y
o
f
 
n
o
n
-
i
n
t
e
g
e
r
s
Figure 3. Plot to check for rounding in the variable ‘white blood cell count’ in three different sites in Study 12.
Site 68 shows evidence of rounding, which in an ongoing trial should be investigated further.
Table 5. Output from the R-program for two sites, comparing the distribution of the first significant digit with the expected distribution
based on (1) Benford’s law and (2) the distribution from all other sites (Study 12 trial)
First digit Expected proportion
(Benford’s law)
Site number 11
Number of data
values (using 26 variables)
Observed
proportion
Observed proportion
from all other sites
1 0.301 343 0.298 0.324
2 0.176 180 0.157 0.155
3 0.125 164 0.143 13.6
4 0.097 155 0.135 0.121
5 0.079 86 0.075 0.072
6 0.067 65 0.057 0.055
7 0.058 54 0.047 0.048
8 0.051 47 0.041 0.043
9 0.046 56 0.049 0.046
p-value – Benford’s law \0.001
p-value – compared
with all other sites
0.77
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2.5 SDs, and all using 2 SDs. However, when several
data values are fabricated within a site, they may
skew the overall mean and SD of log(D). In this
situation fabricated data may not be flagged as
inliers, but they may appear to be discrepant on
visual examination (Figure 5). Grubbs’s test may be
helpful for identifying both true inliers and outliers.
Correlation checks
We examined whether a site appeared different from
others within the same trial using a set of
continuous variables; the output is a grey-scale grid
of squares, where each square represents the correla-
tion between two variables. (Colour could be used
in place of the grey scale.) Pairs of variables with a
correlation coefficient of 1 are indicated by black
squares, those with a coefficient of 21 as white
squares, and everything else as a shade of grey. Dis-
crepant sites tend to have more light or dark squares
than other sites. A formal statistical test using simu-
lations was also applied (see Appendix A – Text 1,
‘Correlation checks’). None of the sites in Study 12
or ABC-02 were flagged, that is, had p\0.01. In the
data from the TOPICAL pretreatment CRF, only two
sites had p \ 0.01; but on closer inspection, neither
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Figure 4. Examining inliers in TOPICAL for 3 sites and 19 variables (i.e., participants who have values too close to the means).
Inliers are identified as having large negative values for log D (y-axis). Each point represents a trial participant, and the point circled (in site 20; in the R-pro-
gram output this shows up as a red circle) is a patient whose d value lies more than 2.5 standard deviations (SDs) below the mean. The program automati-
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Figure 5. Inliers in one site in ABC-02, in which patients (shown as black squares) were manually created to be similar to the means of
several variables. In the left-hand figure, there is one fabricated patient automatically flagged (circled) by the program (22.5 SDs away
from the mean D; in the R-program, output appears as a red circle). But in the right-hand figure, there are two fabricated patients.
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they are apparent on inspection.
SD: standard deviation.
Statistical monitoring in clinical trials 791
http://ctj.sagepub.com Clinical Trials 2013; 10: 783–806
 at University College London on June 25, 2015 ctj.sagepub.com Downloaded from site particularly stood out on the grey-scale plots.
We concluded that the small p-value may have been
influenced by one or two correlations that were
weaker or stronger than in the other sites (Appendix
A – Figure A1). Both the output display and p-values
must be examined when interpreting the results of
these checks.
We tested the program by adding fabricated sites
using two different methods (Appendix A – Text 1).
When sites were created by randomly picking values
for each variable from the values seen in other sites,
one could create plots that appeared strange, with
whole columns that looked strikingly different, but
a p-value just above 0.01, particularly in fabricated
sites with small numbers of patients (e.g., Figure 6,
left panel). When sites were created to have values
around the means of each variable, the correlation
plots tend to have an overall light grey colour,
indicating little correlation. Large fabricated sites
(.25 patients) tend to produce a p-value \ 0.01.
When we ran the R-program 10 times for sites with
30, 35, and 40 fabricated patients, a fake site with
p \ 0.01 was flagged 19 of 30 times. Close inspec-
tion of the output revealed a clear absence of strong
correlations that appeared in all other sites (Figure
6, right panel).
Variance checks for repeated measures data
Variance checks were made for each of four values
from laboratory assays of blood samples taken up to
6 times in Study 12, and 7 such values from up to
18 times in ABC-02. The R-program produced a
table showing the percentage of patients in each site
which fell into the bottom 2.5% of variances (based
on the number of patients checked), and the dis-
plays as in Figure 7 (for platelets in ABC-02). In
Site CHR (72patients)
p=0.9742
Site 999 (10patients)
p=0.026
Site RMA (21patients)
p=0.6142
Site CHR (72patients)
p=0.343
Site 999 (40patients)
p=<0.001
Site RMA (21patients)
p=0.426
Figure 6. Correlation checks for the ABC-02 trial for 9 variables. Each square represents the correlation between a pair of variables (highly
positive = dark colour, highly negative = light colour). Both panels show two real sites (CHR and RMA) and a fabricated site (site 999) gen-
erated using randomly chosen values (left panel) or by choosing values close to the mean of each variable (right panel). The p-value for
each site is based on simulations which count the number of times a site with a correlation matrix as extreme as that observed could be
generated using randomly chosen patients from all other sites.
In both panels, the correlation structure in site 999 appears discrepant. In the left-hand panel, there is a solid dark block (8th variable along), though the
p-value is just above the statistical significance cut-off of 0.01 (i.e., 0.026), because of few patients (n = 10). However, in the right-hand panel, the shading
is generally lighter overall, showing little correlation between variables, in contrast to all other sites, where there are clear correlations (e.g., 4th variable
along and 1 up; 7th variable along and 6 up). With n = 40 patients, the comparison is statistically significant.
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2.5% of concern. Few sites had more than one out-
lying patient, often with only a few repeated mea-
surements; and those sites that did had relatively
large numbers of patients in total, such that the var-
iances did not appear to be unusual.
In the ABC-02 trial, 11 fabricated patients were
added to two sites by an independent statistician;
both sites were flagged by the R-program. Seven of
the 11 patients had variances in the bottom 2.5% of
the distribution for at least 1 of the 7 variables
tested, including one fabricated patient who had
variances which fell in the bottom 2.5% for 4 differ-
ent variables. The two sites with fabricated patients
appeared in the bottom 2.5% of variances for more
variables than any actual trial site. Figure 7 shows
the output for sites 23–33; three fabricated patients
with low variances are highlighted in sites 25
and 31.
The variance check method involves visual
inspection of potentially many displays, with sev-
eral plots for each variable checked. The number of
participants per site, the size of the observed var-
iances, and where the flagged participants fall in
relation to others, must be considered when identi-
fying anomalies. For example, several participants
with low variance who cluster within a site may
indicate fabricated data [20]. Correct transcription
of data from CRFs and other measurements for the
flagged participants should be checked.
Categorical variables
Categorical variables were checked using chi-square
tests which compared each site with all of the remain-
ing sites combined. Two categorical variables were
checked in Study 12. For Eastern Cooperative Oncol-
ogy Group (ECOG) scores and stages, only 5 of 79 and
22 of 79 sites, respectively, had sufficient numbers to
be checked. No site had a p\0.01 for ECOG score but
1d i df o rs t a g e( T a b l e6 ) .C l o s e ri n s p e c t i o no ft h e
observed frequencies revealed no cause for concern.
This R-program is particularly useful for large trials
with many participants in each site in which the main
outcome measure is categorical, for example, response
to treatment. Numbers of deaths or disease progres-
sions also could be investigated using this method.
Adverse events
The R-program flags sites that have very few or too
many participants with adverse events compared
with other sites. We focused on SAEs, but the program
could be adapted to examine any type of adverse
event. A summary table was produced to show sites
from ABC-02 (in which we fabricated data) that are in
the lowest and highest 10th centile of SAE rates. The
rate was calculated as the number of participants with
an SAE in the site divided by the number of partici-
pants and the time the site had been recruiting; an
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Figure 7. Variance checks for ABC-02. There are three fabricated
patients with small variances in site 25 and three in site 31
(shown in shades of red and pink).
Dots of the same colour belong to the same patient. The R-program auto-
matically assigns a non-black colour to participants with outliers.
Table 6. Example of output from the checks of a categorical vari-
able, using the baseline stage in Study 12.
(a) Details of the test for each site.
Stage Site frequency All other sites’
frequency
Site: 41
Limited 1 (7.7) 367 (51.6)
Extensive 12 (92.3) 344 (48.4)
Chi-square p 0.004
Site: 45
Limited 12 (46.2) 356 (51.0)
Extensive 14 (53.9) 342 (49.0)
Chi-square p 0.77
(b) p-value for each site tested (can be examined quickly, exam-
ple shows the 5 sites).
Site p-value
36 0.332
37 0.186
41 0.004
44 0.328
45 0.775
Baseline stages were compared using a chi-square test. Each site (with
enough patients) was compared to all of the remaining sites combined.
Results are output in two spreadsheets.
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Any centile value can be specified in the R-program.
Sites that required further investigation had a reason-
able number of participants followed for several
months, but had few or no SAEs. We ran simulations
by adding a fabricated site to the ABC-02 data 625
times, covering all combinations of numbers of
patients (5, 10, 25, 35, or 45), lengths of time in the
trial (5, 10, 15, 30, or 45 months), and numbers of
patients with SAEs (from 1 to all patients).
Figure 8 is an example of one of the output dis-
plays of the rate of SAEs versus the number of parti-
cipants at each site. The circled black square is the
fabricated site (specified as being open for 45
months, having recruited 35 patients but having
recorded only 6 SAEs).
From the simulations, we also attempted to spe-
cify the maximum number of SAEs that a site could
have but still appear in the bottom 10% of rates
(Appendix A – Table A4); for example, in a site with
25 patients which had been open for 30 months,
there could be  9 patients with an SAE and it would
still fall within the bottom 10% of all sites. Such
sites, which would fall in the bottom right-hand
side of the display in Figure 8 (small SAE rates and
relatively large numbers of patients), may warrant
further investigation.
The method described above uses an estimated
overall time (i.e., time from first randomisation until
last randomisation plus ‘x’ months, where ‘x’ is spe-
cified as the number of months in which SAEs are
expected, i.e. slightly longer than the treatment
time. We also used another method of calculating
the SAE rate, based on the time spent in the trial by
each participant, from date of randomisation
through date last seen (Appendix A – Text 1,
‘Adverse events’). Using this approach, the two lar-
gest sites were flagged by the R-program because of
the long times during which they accrued partici-
pants (Appendix A – Figure A2). However, close
inspection of the output revealed that their rates
were actually larger than the overall rate, although
below the median per site, and the total number of
SAEs recorded was relatively high, with one site hav-
ing recorded 65 SAEs for 46 patients and the other
54 SAEs for 32 patients.
Strengths and limitations
The strengths and limitations of each R-program are
summarised in Table 3. In most cases, the main lim-
itation to interpretation of output from the programs
is the size of the trial. The methods to detect data
errors can be applied to all trials; however, many of
the methods that aim to detect fraud would be diffi-
cult to apply reliably in small trials, or even larger
trials when small numbers (\1 0 )o fp a r t i c i p a n t sa r e
recruited within each site.
Furthermore, the programs that examine possible
fraud were created using certain assumptions about
the way fabricated data would be generated; when
these assumptions are incorrect, that is, a researcher
is ‘too good’ at faking data, fraud may not be
detected.
Another difficultly is that several methods rely on
a visual assessment of output displays, and for these,
we added formal statistical tests to aid interpreta-
tion. However, the displays should be readily inter-
preted once the user has gained experience in
applying the R-programs, and we stress that the out-
put from no single program should be used as defi-
nite evidence of any irregularity at a site.
Finally, we have applied the methods, implemen-
ted in the R-programs, only to trials in which fraud
was unlikely to have occurred; therefore, we had to
fabricate data ourselves to evaluate some methods.
We encourage readers to help refine and improve
these R-programs by applying the methods to their
own databases.
Discussion
We have summarised several methods of CSM by
illustrating their application to data from three trials
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Figure 8. Examining SAE rates (ABC-02).
SAE: serious adverse event.
Each point represents a site. The y-axis is the SAE rate per site, allowing for
the number of patients and the time the site has been recruiting. The low-
est 10% of SAE rates are shown as black squares, and the highest 10% as
solid black circles. The circled observation is one of the fabricated sites
added during the simulations, and identified as having a low SAE rate com-
pared to the average for all sites (horizontal line). Sites furthest towards the
bottom right could have on-site monitoring checks.
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method (Table 3). Although the methods are not
perfect, they are easy to implement and interpret.
Importantly, they identify certain data errors, such
as incorrect dates and outliers, far more quickly
and easily than one would during usual data edit-
ing and correction processes. They also may help
to detect fraudulent sites or participants when
fraudulent data are generated in a manner consis-
tent with the assumptions that are the basis of the
methods.
The R-programs can be executed automatically
and the output should be examined by suitably
trained staff. On-site data monitoring visits could be
targeted for sites that appear discrepant to the
others. During visits to other sites, resources could
focus on other on-site activities, such as staff train-
ing, helping with accrual, documentation of
informed consent, and pharmacy and adverse event
checks.
Participant-level data monitoring often is per-
formed during data entry, using automatic valida-
tion checks within the database. However, the
methods we describe here are not easily pro-
grammed into many database systems. Methods
such as the correlation check, the inliers, and digit
preference program could be applied to as many
variables as desired to look for unusual patterns, but
we recommend that checks to identify errors and
rounding and testing the distributions of categorical
data be limited to variables associated directly with
safety, treatment compliance, and the primary effi-
cacy end points.
Central site-level monitoring considers both
visual assessments of data displays and formal statis-
tical tests. Sites will, by chance, be flagged by one of
the methods. Therefore, to avoid too many centres
being flagged as suspicious, no single data check
should be used automatically trigger an on-site visit.
CSM should guide the depth of investigation of
anomalies. Consistency of findings from several
checks should be used to determine whether a parti-
cular centre is identified as suspicious [18]. When
we applied the four tests designed to detect poten-
tial fraud (digit preference, inliers, correlations, and
variance checks) to Study 12, only two sites were
flagged by more than one test. Both sites were
flagged by the digit preference program and both
contained a patient inlier. Further investigation and
checks ruled out fraud. More detailed checks also
could be performed when a centre is flagged as sus-
picious before undertaking on-site investigation. For
example, if a site reported a particularly low number
or rate of SAEs, a first step could be to compare the
baseline characteristics of participants enrolled at
this site with participants at other sites.
Our R-programs were based on methods suggested
by others [15–18]. Although these articles discussed
types of fraud and possible methods of detection,
only one applied some of the methods to real data
[18]. O’Kelly [28] fabricated participants and a
blinded statistician applied methods for inliers, out-
liers, and unusual correlation structures [18] com-
paring the results between sites. We agree with
O’Kelly who suggested that the actual values of the
correlation matrix should be examined, rather than
just looking at how different the overall structure is.
We did not cover Statistical Process Control (SPC)
for clinical trials [29,30]. Most SPC methodology is
based on the use of control charts for monitoring a
process over time. Similar methods could be used to
monitor clinical trials, for example, tracking the
average number of SAEs per participant in each trial
arm over time.
At present, paper CRFs are used to report data in
many trials, including all trials run within our Clini-
cal Trials Unit (CTU) and 57% of Canadian trials
[31]. In our vision for the future, a Personal Data
Assistant (PDA) would be used for collecting partici-
pant data. The PDA would check the data being
entered and warn when a possible error was being
made or for missing data. At the end of data entry,
the forms would be automatically transmitted to
the database in the coordinating centre. Participant
and centre-level checks, and trial level summaries,
would be generated automatically. Trial staff could
choose from a menu that allows interactive looks at
the data of the types we summarise in our article.
For example, for participant-level monitoring, a
panel of tables and graphs could appear with demo-
graphic details, event dates, missing data, and time
plot of when SAEs were recorded. At the site level,
there would be a panel showing recruitment graphs,
a control chart for SAEs, a control chart for deter-
mining the level of on-site monitoring and various
fraud test results, and tables and graphs of differ-
ences between centres.
In conclusion, CSM can be a cost-effective and
worthwhile alternative to on-site source data verifi-
cation. It can identify anomalous participant data
that may be incorrect or fabricated, and sites where
the data considered together are quite different from
all other sites and therefore should be investigated.
The methods are relatively simple to implement and
interpret.
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Appendix A
To run the R-programs automatically, the variables
must appear in a specific order within the data set.
To avoid the problem of different trials using differ-
ent variable names, all of the programs are based on
the order in which the variables are given; that is,
the participant identification (ID) number must be
in the first column and the site name/number in the
last (in most cases).
Text 1
Details of the methods used
Participant-level data monitoring
1. Date checks
For each participant, all dates should occur after the
first participant was randomised (or registered for
single arm studies), and before final events such as
death and the end of the trial (defined as the date
the database was locked or the current date).
Another check that can be made is whether certain
dates fall on weekends or national holidays, when
for some trials registration, randomisation, and
some clinic appointments are unlikely to fall on
these days. Care must be taken in choosing which
dates to check, because dates of death, emergency
treatment, or some clinic visits may occur at any
time. The date_order_check program performs checks
to detect dates which do not fall in the correct order
and the weekend_hol_check program looks for dates
which fall on a weekend or a national holiday.
2. Outliers
Outliers are observations which appear to be incon-
sistent with the rest of the data, usually appearing as
too large or too small. Occasionally, we expect to
observe some extreme values (especially from highly
skewed distributions), and so these would not really
be outliers. The methods we summarise here apply
to any continuous measurement, and they compare
the observed value for a single participant to those
from all other participants. Outliers at the partici-
pant level are more likely to result from errors rather
than fraud, because those who fabricate data try not
to make them stand out too much from the rest to
avoid detection (‘Inliers’). Barnett and Lewis [32]
comprehensively cover the theory of outliers and
associated tests. Both univariate and multivariate
checks can be examined using the outlier_check R-
program.
Univariate outliers (each variable considered separately):
One method involves finding the mean and stan-
dard deviation (SD) for a single continuous variable
over all sites and comparing each participant’s value
against these. For example, when checking body
weight, we specify a value ‘k’ in the outlier_check pro-
gram, and all participants whose value is more than
6k SDs from the mean are flagged (Standard Devia-
tion method). A value of k = 2 should yield approxi-
mately 5% (expected from a Normal distribution)
and so could represent too many data checks. We
therefore used k = 3 (though k = 2.5 is acceptable).
The second method is based on Grubbs’s test, which
is similar to the Standard Deviation method, but it
examines outliers iteratively; the most extreme value
is identified and then removed before looking for
the second most extreme value, and so on. Remov-
ing outliers each time will reduce the SD and pre-
vent masking (i.e., extreme observations hidden or
‘masked’ by those even more extreme).
Multivariate outliers (several variables considered
simultaneously):
Buyse et al. [16] suggest using the squared Euclidean
distance from the mean for the detection of both
multivariate inliers and outliers. This method aims
to identify participants who have outliers for several
variables (these may or may not represent data
errors because a participant with a genuine extreme
measurement for one variable might have similar
extreme values for other variables). The value xij
represents a measurement for participant i and vari-
able j. The difference between xij and the mean of
that variable over all participants (in all sites) (i:e:   xj)
is then divided by the SD for all participants (Sj) and
squared
Di =
X
j
xij     xj
Sj
   2
Each participant then has a value Di (based on sev-
eral variables), and the mean of these over all parti-
cipants is D. We can specify ‘k’ (e.g., k = 3) in order
to list participants who have a high Di (i.e., more
than k SDs from the overall mean D). Large Di
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ered together are more extreme. Aspects such as elig-
ibility criteria could thus be checked.
We also developed a program to calculate the
Mahalanobis distance. This is similar to the Eucli-
dean distance, but also takes into account the corre-
lation structure of the data: the distance, Di, of the
vector observation, xi, to the mean vector, x,i sc a l -
culated as
Di =
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
xi     x ðÞ
9S 1 xi     x ðÞ
q
where S is the observed covariance matrix. Observa-
tions with large Di values may be potential outliers.
The Mahalanobis distances should follow a chi-
square distribution (for Normally distributed data),
so the extreme values can be selected as those which
exceed a critical value (based on a probability level
specified when running the program).
Centre (site) level data monitoring
Checks performed at the centre level have two pur-
poses. First, to identify systematic errors in trial con-
duct at a site (procedural errors), for example, due to
the protocol not being followed correctly, incorrect
measurement or recording of some variables, or
adverse events are over or under-reported. These
could be due to a genuine misunderstanding of the
trial protocol by local staff. The second purpose is to
detect fraud, that is, creating trial participants and
associated data, or inventing data for real partici-
pants who have missing values [15]. The methods
described below aim to flag a site that is discrepant
to the rest, in order to consider an on-site visit for
checking the procedures and original data.
1. Rounding and digit preference
We used two methods to identify whether too many
data values are being rounded to a whole integer
(procedural error), or whether data are being created
(fraud).
The first, proposed by Taylor et al. [18], implemen-
ted with the integer_check R-program, examines the
pattern of integers recorded over time (details in
Table A5). A plot for each site is produced, in which
there is a monotonic increase (line of identity) if all
the numbers are non-integers; too much rounding
shows up as horizontal lines.
The second method uses Benford’s law [22] to
identify falsified data. In many naturally occurring
situations, the distribution of the first significant
digit of any numeric variable is as follows: the prob-
ability that the first digit is i (where i = 1–9) is
approximately log10(i+1)   log10(i) [33]. Therefore,
there should be about 30% leading 1s and only 6%
leading 7s. The rule works best when examining
many different variables at once. Benford’s law is
useful because people tend to be poor random num-
ber generators, so if they create false data, the law
should break down. The digit_preference R-program
examines all the specified numeric variables on a
case report form (CRF) and applies a chi-square test
to see whether the observed distribution of leading
digits is very different from that expected [34]. How-
ever, Benford’s law should only be used when the
first digit can range between 1 and 9, so measure-
ments restricted to say 100–300 cannot be used. In
addition, the law tends to not fit some distributions
(e.g., Gaussian). Because of these limitations, we also
compared the distribution of leading digits from
each site with that from all other sites together,
using a chi-square test:
x2
test =
X 9
j=1
Si,j   Ai,j
   2
Ai,j
 !
Ni
Si,j =
#leading digitsjinsitei
#observationsinsitei
Ai,j =
#leading digitsallsitesi 6¼ j
#observationsinallsitesi 6¼ j
Ni =#observationsinsitei
2. Comparing means of variables between centres
Comparing the means of several variables between
centres is best done graphically, for which there are
various techniques [16,18,35]. One method is
Chernoff faces, where each site is represented by a
cartoon face, and the means of the variables deter-
mine the size and shape of various features of the
face (eyes, nose, and so on). We developed programs
to examine many variables simultaneously. Chern-
off faces (mean_check R-program, using the aplpack
[27] package) are potentially useful because people
should be able to recognise differences between
faces easily. If a particular site has mean values that
are very different from the others, it might indicate
that some participants have been fabricated, or
those recruited are so different to other centres that
they require investigation. The plots could also be
used to examine baseline measurements, to see
whether eligibility criteria are being followed cor-
rectly. Star plots (mean_check, using the aplpack [27]
package) have a principle similar to Chernoff faces,
in which each branch and each point of a star
(a site) represent a different variable, and the length
of these two features is determined by the means.
798 AA Kirkwood et al.
Clinical Trials 2013; 10: 783–806 http://ctj.sagepub.com
 at University College London on June 25, 2015 ctj.sagepub.com Downloaded from Parallel coordinate plots simply plot the means
of each variable at each site, joining the points
together with a different colour line for each
site.
Text 2
Comparing means of variables between centres
Chernoff face plots were obtained for 15 blood mea-
surements in Study 12 (Figure A3). Sites 11, 59, and
78 appear discrepant to the others. The R-program
produces summary statistics to examine the data
further in unusual sites (Table A6). Much of the dif-
ferences were due to the presence of extreme out-
liers for a few participants. While Chernoff faces are
visually appealing, they have several limitations.
First, the assessment is subjective. Second, the facial
characteristics are heavily influenced by outliers,
which if not identified and corrected beforehand,
would make a site appear more discrepant than it
really is. Removing extreme outliers from a site will
change the features of the face both at the site and,
to a lesser extent, all other sites (Figure A4). Site 11
does not appear as visually different to the other
sites in Figure A4, as it does in Figure A3. Third, large
differences could be missed depending on which
facial feature is selected to represent each variable;
for example, visually examining differences in the
height of the eyes or nose width is more difficult
than, for example, width of the mouth or hair.
Therefore, the most important variables could be
linked to features whose shape is more readily dis-
tinguishable. Fourth, although the human eye can
often identify unusual patterns, choosing discrepant
sites for trials with many (e.g., .50) centres is not
easy. Fifth, Chernoff faces work with exactly 15 vari-
ables (because of 15 different features to manipu-
late). If there are more than 15 variables, only the
first 15 are included, and if there are fewer, the first
variables will be included multiple times until there
are 15 in total.
Star plots (Figure A5) and parallel coordinate plots
(Figure A6) are shown for Study 12, based on the
same variables as in Figure A3. An advantage of both
of these is that variables have equal weight on the
plot, compared to Chernoff faces where the match-
ing of variables to features is subjective. However,
the star plot is difficult to interpret because there are
many branches, and there is no easy way to tell
which variable is associated with each branch.
Although the parallel coordinate plot appears simi-
larly confusing at first, it can easily be investigated
interactively, but only if the appropriate software is
available (e.g., JMP, SAS). However, this cannot be
done in R automatically. Star and parallel coordinate
plots, like Chernoff faces, are also affected by a few
participants with outlying data values.
3. Inliers
Examining inliers could identify data that are too
similar to the rest (instead of too different, that is,
outliers). However, if data are fabricated, people
tend to choose values close to the mean of the other
observations, so that they would not be readily
noticed [15–18]. It would be unusual for a genuine
participant to have most or all of their variable
values around the mean. Inliers can be detected
using the same calculations as in multivariate out-
liers for participant-level data checks (‘Outliers’),
that is, for each participant i and several variables,
we have the sum Di. Differences show up more
clearly on a logarithmic scale, where the smaller the
differences from the overall mean, the larger and
more negative the value of log(Di). Having several
participants with very small Di in the same site may
require further investigation. In our program
inlier_check, we specified 23 SDs lower than the
mean of log(D), over all participants.
Because few inliers were found with the observed
data, we fabricated participants and data (in ABC-
02) close to the mean values, using values for each
variable that fell within ks of the mean of the
observed data, where s is the observed SD of the
variable and k was a small value (one fabricated par-
ticipant for each of k = 0.5, 0.4, 0.3, 0.25, 0.2, and
0.1). This test was performed for one small site (9
participants), one medium site (18 participants),
and one relatively large site (49 participants).
4. Correlation checks
The method here (correlation_check R-program)
examines correlations between variables within a
site and then compares the correlation structures
between sites [18,28]. The premise is that even if a
researcher has created false data and used sensible
values for a single variable, it is difficult to fabricate
several variables that together are consistent with
real data.
We can select a set of continuous variables from
one CRF, and the R-program calculates the pairwise
correlation matrix between these variables for each
site (rx,y). These can be displayed using a grey-scale
plot (using the gplots [36] package). This plot creates
a grid of squares (one square represents a correlation,
and the colour depends on the size of the correlation
coefficient. Sites with high positive correlations are
black, high negative correlation are white, and
everything else a shade of grey, with lighter greys for
the correlations nearer 21 and darker greys for the
correlations closer to +1.
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site appears different. The program can also
perform a formal test to compare the correlation
structure of each site with the overall correlation
structure.
The formal test calculates a value of d*, where d*
is the sum of the squared differences between the
correlations in each site and the correlations in all
the data (using the pairwise correlation matrix for
all data, Rx,y)
d  =
X
x,y
x 6¼ y
rx,y   Rx,y
   2
The program then generates 1000 ‘pseudo’ sites for
each real site. For example, if there are 30 partici-
pants in site Z, 1000 ‘pseudo’ site Zs are created by
randomly selecting 30 participants out of all those
in the trial. The value of d* for each site is calculated,
and a count is set up to record how many of these
d* values exceed the d* for our chosen site. If fewer
than 1% (or another pre-specified value) are larger
(this percentage is our p-value) we conclude there
may be reason to be suspicious and should perhaps
have a closer look at the data.
To examine this method further, we created sites
(for the ABC-02 trial) and compared them with the
genuine ones. This was done by removing one large
site from the data set and creating new ones with
varying numbers of patients (10, 15, 20, 25, 30, and
35). The new sites were created in two different
ways. In the first method, we generated patients by
randomly choosing a value for each continuous
variable from all of the values of that variable in the
removed site. The second method involved ran-
domly generating values for each variable from a
Normal distribution with the mean and SD calcu-
lated from the removed site. Any values below or
above the lower and upper limits observed in the
removed site were generated again. This is perhaps a
more realistic method of data generation as it would
favour values close to the mean. Both methods
involve creating data for each variable separately,
without considering its correlation with any other
variable. The results were similar using either
method: the fabricated sites were the only ones that
produced a p-value\0.01.
5. Variance checks for repeated measures
Evans [15] suggested looking at the variance of
repeated measurements, and we used a technique
[20] which examines variances when there are
multiple records for each participant (variance_check
R-program). Important continuous variables are
selected, and the variance of these for each
participant is found. The mean and SD of the var-
iances between participants is calculated, and any
individual whose variance is more than 6k SDs from
the mean are flagged (e.g., k = 3). If data are fabri-
cated, it might be difficult to do so over several time
points, because the false values may not vary
enough compared to real data.
Sometimes, the SD of the variances could be large
in comparison to the mean, so participants with
small variances are unlikely to be detected. To over-
come this, if the mean minus SDs is less than zero,
the lowest 2.5% of participants in that site are also
identified.
The continuous variable is plotted against an
index number which orders participants, first by site
then by date of randomisation, in a scatter plot. Par-
ticipants with extreme values are automatically
plotted in different colours to make it easier to see
whether several appear in the same site. Small var-
iances could indicate fabricated data, where the data
are too similar to the other measurements for the
participant, and these are coloured in shades of red/
pink. Participants with large variances (possible data
errors) are coloured in shades of blue.
An option is included in the R-program to look for
zero change between repeated measurements (rather
than small variance). This removes the problems
caused by large outlying values distorting the overall
variance; however, it may only be useful to identify
procedural errors (investigators writing down pre-
vious test results) rather than falsified data.
6. Categorical variables
Most of the data checks above are meant for contin-
uous variables. The R-program cat_check can be used
for categorical variables. It compares the number of
observations at each level in a given site with the
frequency distribution seen in all of the other sites.
Frequency tables for each site are provided in the
output, including a chi-square test on sites that have
an expected count of  5 participants in each level
(or other specified minimum), and p-values.
7. Adverse events
In trials of participants who are already ill (patients),
interest is often in serious adverse events (SAEs), and
these are the ones that must be reported to the coor-
dinating centre. In studies of healthy participants,
SAEs might be uncommon, so there could also be
interest in mild or moderate events. The following
method can be applied to any definition of adverse
event, but the purpose is to identify sites that appear
to have too few, which may require an on-site visit.
When examining the number of SAEs per site, we
need to allow for the number of participants
recruited, as well as the length of time in the trial.
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site, we calculated the SAE rate as the number of
participants with at least one SAE divided by the
total number recruited, which is further divided by
trial duration at that site. The trial duration at each
site is taken as the time between the first randomisa-
tion and the last expected SAE report date/date of
data dump (whichever comes first). The date of the
last expected SAE report is calculated as the date of
the last randomisation plus the number of months
we expect to receiving SAEs; for example, if a treat-
ment lasts 6 months, we may add 7 months for the
SAE reports to be sent to the coordinating centre.
This SAE rate is plotted against the number of
recruited participants in the site. The SAE_check
R-program identifies centres with the highest and
lowest 10% of rates (or alternative proportion) and
shows all sites in relation to the average SAE rate for
the whole trial.
We also had another approach where the duration
in the trial for each participant was used instead of
overall duration at the site. However, we still limited
the number of days each participant could contri-
bute to the total duration, by only covering the per-
iod in which we expect to receive SAEs (i.e., slightly
longer than the time the participant is on treat-
ment). This is because in trials where participants
have long life expectancies, those sites which
opened early may have many participants with long
follow-up times, falsely deflating the SAE rate in
comparison to those which had opened more
recently.
The key aspect is to flag centres that are relatively
large, but with a low number of SAEs (because low
rates could arise by chance from centres with few
participants).
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the Study 12 trial (of 79 recruiting sites, 66 were examined, and 37 of these are shown below)
Site ID
number
Number of
data values
Number of
patients
Chi-square
p-value comparing
observed % with
Benford’s law
(26 variables)
Chi-square
p-value comparing
observed % with
observed % from
all other sites (26 variables)
1 295 8 0.006 0.277
2 359 10 0.167 0.616
3 337 8 0.19 0.345
4 436 11 0.048 0.062
5 548 15 0.025 0.781
63 7 9 9\0.001 0.130
7 380 14 0.197 0.759
8 278 7 0.205 0.608
9 359 10 0.263 0.174
10 138 3 0.399 0.916
11 1150 27 \0.001 0.767
12 358 10 0.043 0.509
14 1041 31 \0.001 0.003
15 194 7 0.046 0.058
16 525 13 0.009 0.192
17 295 8 0.209 0.213
19 338 10 0.261 0.453
. .
. . .
. . .
. . .
. . .
.
58 605 17 0.005 0.186
59 188 5 0.022 0.001
60 530 12 0.006 0.003
62 117 4 0.132 0.084
63 244 7 0.007 0.011
64 160 4 0.144 0.119
66 186 4 0.386 0.383
69 212 6 0.011 0.109
70 120 3 0.073 0.061
71 252 7 0.005 0.140
72 501 12 0.469 0.989
73 356 9 0.105 0.801
75 282 7 0.204 0.391
76 291 7 0.189 0.761
78 161 7 0.654 0.868
79 224 5 0.101 0.776
81 469 13 0.163 0.850
83 250 6 0.007 0.251
88 192 6 0.146 0.359
93 161 4 0.524 0.783
ID: identification.
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to the data
Site ID code Rate Patients with an SAE Total number of SAEs Number of patients Time in trial (months)
Lowest 10%
ARI 0 0 0 1 5.5
BRI 0 0 0 1 5.5
SOU 0.004 1 1 8 34.08
UCL 0.008 5 5 18 33.29
WES 0.009 1 1 4 26.43
FAKE 0.010 9 9 25 35.46
Highest 10%
DRI 0.082 2 2 2 12.20
SAL 0.115 2 2 2 8.72
BEL 0.155 5 6 5 6.45
DUN 0.182 1 1 1 5.5
GLA 0.182 1 1 1 5.5
WRE 0.182 1 1 1 5.5
SAE: serious adverse event; ID: identification.
Output from the R-program that lists sites that have SAE rates in the lowest and highest 10th centile in ABC-02.
Table A3. A fabricated site with 35 patients, 6 SAEs and 45 months between the first and last randomisation
Site ID code Rate Patients with an SAE Total number of SAEs Number of patients Time in trial (months)
Lowest 10%
ARI 0 0 0 1 5.5
BRI 0 0 0 1 5.5
FAKE 0.003 6 6 35 50.48
SOU 0.004 1 1 8 34.08
UCL 0.008 5 5 18 33.29
WES 0.009 1 1 4 26.43
Highest 10%
DRI 0.082 2 2 2 12.20
SAL 0.115 2 2 2 8.72
BEL 0.155 5 6 5 6.45
DUN 0.182 1 1 1 5.5
GLA 0.182 1 1 1 5.5
WRE 0.181818 1 1 1 5.5
SAE: serious adverse event; ID: identification.
Table A4. The maximum number of patients with an SAE that a site can have for it to fall within the bottom 10% of all sites, for specified
numbers of patients and lengths of time in the ABC-02 trial. The numbers in the table below would differ for other trials, where the SAE
rate is different
Patients Time in trial
a (months)
51 01 53 04 5
5 0 0 112
1 0 1 1 235
25 2 4 5 9 13
3 5 35 71 31 9
50 5 8 11 19 27
SAE: serious adverse event.
aTime between the first and last recruitment + 5.5 months.
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Participant index Body weight (kg) Date (in order) X Cumulative sum of X
1 75.5 11 January 2010 1 1
2 65.3 13 January 2010 1 2
3 68 22 January 2010 0 2
4 89.6 01 February 2010 1 3
5 90 02 February 2010 0 3
6 64 18 February 2010 0 3
7 78.8 17 March 2010 1 4
8 55.7 24 March 2010 1 5
. .
. . .
. . .
. . .
. . .
.
The table is based on participants from the same site.
For example, consider baseline body weight. The weights are ordered by the date recorded, and a binary variable (X) is generated to record whether it is an
integer (X = 0) or not (X = 1). The cumulative sum of X is then plotted against the participant index. If all the body weights were non-integers, this would
form the line y = x. The line will be horizontal where an integer is recorded. If a site appears to have periods with many integer values in a row or more fre-
quent integer values than other sites, then this site could be investigated to check that their staff understands the correct level of accuracy required.
Table A6. Summary statistics for site number 78 in Study 12 that appeared to be unusual, when examining the Chernoff faces diagram
(Figure A3). The table shows the individual data values for 7 patients and 4 variables
Patient ID wbc alt alp LDH
1 17.53 N/A N/A N/A
2 13.69 N/A 203 317
3 19.74 24 301 270
4 10.4 21 284 520
5 15.12 N/A 130 N/A
6 15.24 N/A 1728 4848
7 18.47 N/A N/A 577
Site means 15.74 22.5 529.2 1306.4
Overall means 10.66 41.40 148.10 732.69
Facial feature controlled Face; width Eyes; height Eyes; width Hair; width
ID: identification.
A single patient with large outliers (highlighted) has skewed the site means for two variables (pre-treatment alkaline phosphatase (alp) and lactate dehydro-
genase (LDH)). These patients were also picked up by the outliers R-program. The ‘alt’ variable (alanine aminotransferase) had a site mean about half the
overall mean, but this was based on just two values: there was much missing data. The ‘wbc’ (white blood cells) variable has a high mean relative to the
overall value but no outliers – this site could be investigated to see whether the values were being recorded correctly.
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Site 19 (25patients)
p=0.0018
Site 16 (37patients)
Site 11 (34patients) Site 3 (10patients)
Figure A1. Correlation checks for the TOPICAL trial using 16
variables (each square represents a correlation between a pair of
variables). Sites 11 and 19 were the only two that had p-values
below 0.01.
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Chernoff face plots by site
Figure A3. Chernoff faces for a single case report form (start of
chemotherapy) for the Study 12 trial (15 variables).
Three sites (11, 59 and 78) appear visually to be discrepant to the others.
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Figure A2. Examining SAE rates (ABC-02).
SAE: serious adverse event.
Again each point represents a site, the y-axis is the SAE rate per site, allow-
ing for the number of patients and the time in the trial. The lowest 10%
of SAE rates are shown as black squares and the highest 10% as solid black
circles. However, in this version, the time in the trial is taken as the sum of
the time each patient has been in the trial (cut-off at 5.5 months per
patient) to create the rate rather than the time the site has been open.
Note that the two biggest sites fall within the bottom 10% (shown as
black squares).
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Chernoff face plots by site
Figure A4. Chernoff faces for a single case report form for Study
12 (start of chemotherapy form; 15 variables) after one partici-
pant with a single outlier for one variable in site 11 had been
corrected.
Site 11 appeared unusual in Figure A3, but not so much now.
Star plots by site
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Figure A5. Star plot for a single case report form (start of che-
motherapy) for Study 12 trial (15 variables).
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Figure A6. Parallel coordinate plot for a single case report form
(start of chemotherapy) for Study 12 trial (14 variables).
Each coloured line represents a different centre.
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